These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 30446695

  • 1. Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model.
    Ndumnego OC, Koehler SM, Crafford JE, Beyer W, van Heerden H.
    Sci Rep; 2018 Nov 16; 8(1):16937. PubMed ID: 30446695
    [Abstract] [Full Text] [Related]

  • 2. Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.
    Koehler SM, Buyuk F, Celebi O, Demiraslan H, Doganay M, Sahin M, Moehring J, Ndumnego OC, Otlu S, van Heerden H, Beyer W.
    BMC Vet Res; 2017 Jul 12; 13(1):220. PubMed ID: 28701192
    [Abstract] [Full Text] [Related]

  • 3. Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model.
    Ndumnego OC, Köhler SM, Crafford J, van Heerden H, Beyer W.
    Vet Immunol Immunopathol; 2016 Oct 01; 178():14-21. PubMed ID: 27496738
    [Abstract] [Full Text] [Related]

  • 4. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
    Welkos S, Little S, Friedlander A, Fritz D, Fellows P.
    Microbiology (Reading); 2001 Jun 01; 147(Pt 6):1677-1685. PubMed ID: 11390699
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.
    Gauthier YP, Tournier JN, Paucod JC, Corre JP, Mock M, Goossens PL, Vidal DR.
    Infect Immun; 2009 Mar 01; 77(3):1197-207. PubMed ID: 19114543
    [Abstract] [Full Text] [Related]

  • 7. Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.
    Cybulski RJ, Sanz P, McDaniel D, Darnell S, Bull RL, O'Brien AD.
    Vaccine; 2008 Sep 08; 26(38):4927-39. PubMed ID: 18657585
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Detoxified lethal toxin as a potential mucosal vaccine against anthrax.
    Xu Q, Zeng M.
    Clin Vaccine Immunol; 2008 Apr 08; 15(4):612-6. PubMed ID: 18256208
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. BclA and toxin antigens augment each other to protect NMRI mice from lethal Bacillus anthracis challenge.
    Köhler SM, Baillie LW, Beyer W.
    Vaccine; 2015 Jun 04; 33(24):2771-7. PubMed ID: 25917676
    [Abstract] [Full Text] [Related]

  • 12. Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits.
    Lee DY, Chun JH, Ha HJ, Park J, Kim BS, Oh HB, Rhie GE.
    FEMS Immunol Med Microbiol; 2009 Nov 04; 57(2):165-72. PubMed ID: 19732139
    [Abstract] [Full Text] [Related]

  • 13. Anthrax spores make an essential contribution to vaccine efficacy.
    Brossier F, Levy M, Mock M.
    Infect Immun; 2002 Feb 04; 70(2):661-4. PubMed ID: 11796596
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.
    Williamson ED, Hodgson I, Walker NJ, Topping AW, Duchars MG, Mott JM, Estep J, Lebutt C, Flick-Smith HC, Jones HE, Li H, Quinn CP.
    Infect Immun; 2005 Sep 04; 73(9):5978-87. PubMed ID: 16113318
    [Abstract] [Full Text] [Related]

  • 15. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
    Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P.
    Proc Natl Acad Sci U S A; 2004 Sep 14; 101(37):13601-6. PubMed ID: 15342913
    [Abstract] [Full Text] [Related]

  • 16. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
    Mendelson I, Gat O, Aloni-Grinstein R, Altboum Z, Inbar I, Kronman C, Bar-Haim E, Cohen S, Velan B, Shafferman A.
    Vaccine; 2005 Dec 01; 23(48-49):5688-97. PubMed ID: 16039760
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity of Non-Living Anthrax Vaccine Candidates in Cattle and Protective Efficacy of Immune Sera in A/J Mouse Model Compared to the Sterne Live Spore Vaccine.
    Jauro S, Ndumnego OC, Ellis C, Buys A, Beyer W, Heerden HV.
    Pathogens; 2020 Jul 10; 9(7):. PubMed ID: 32664259
    [Abstract] [Full Text] [Related]

  • 18. A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis.
    Majumder S, Das S, Somani V, Makam SS, Joseph KJ, Bhatnagar R.
    Sci Rep; 2018 May 08; 8(1):7242. PubMed ID: 29740033
    [Abstract] [Full Text] [Related]

  • 19. Comparisons of the humoral and cellular immunity induced by live A16R attenuated spore and AVA-like anthrax vaccine in mice.
    Lv J, Zhang YY, Lu X, Zhang H, Wei L, Gao J, Hu B, Hu WW, Hu DZ, Jia N, Feng X.
    Biologicals; 2017 Mar 08; 46():130-138. PubMed ID: 28215694
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model.
    Jo SK, Ahn BE, Choi EH, Kang JE, An H, Oh MD, Rhie GE.
    Vaccine; 2020 Feb 11; 38(7):1586-1588. PubMed ID: 31911031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.